Date:12/14/2011

the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

 Champions Oncology, Inc.Reconciliation of GAAP to Non-GAAP Net Loss(Amounts in thousands except for loss per share amounts) 

Three Months Ended

October 31,

 

Six Months Ended

October 31, 

2011

2010

 

2011

2010Net loss attributable to Champions – GAAP

($2,349)

($54)

 

($4,386)

($645)Less:

Stock-based compensation

 

855

 

197

 

 

1,867

 

367Net income (loss) attributable to Champions-non-GAAP:

($1,494)

$143

 

($2,159)

($278) 

Net income (loss) per common share attributable to Champions – non GAAP:

 

 

 

 

 Basic and diluted

($0.03)

$0.00

 

($0.05)

($0.01) 

CONTACT:
Susan Foreman
Champions Oncology, Inc.
+1-410-369-0365

'/>"/>

SOURCE Champions Oncology, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Champions CFO Resigns
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California